[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564110":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":41,"responsibleParty":60,"collaborators":62,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":31,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":31,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Oxford","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Losartan","EXPERIMENTAL","50 mg single-dose losartan",[13],"Drug: Losartan potassium 50mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Microcellulose placebo in identical capsule",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Losartan potassium 50mg","Single dose losartan (50 mg), encapsulated identically to placebo.",[9],[9,27],"Cozaar",{"type":6,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"Single tablet encapsulated identically to placebo.",[15],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Andrea Reinecke, PhD","CONTACT","01865 618320","andrea.reinecke@psych.ox.ac.uk",{"name":39,"role":35,"phone":31,"phoneExt":31,"email":40},"Divya Prasad, MSc","divya.prasad@psych.ox.ac.uk",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Warneford Hospital","RECRUITING","Oxford","Oxfordshire","OX37JX","United Kingdom","UK",{"type":51,"coordinates":52},"Point",[53,54],-1.25596,51.75222,{"lat":54,"lon":53},[57,58],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},{"name":34,"role":59,"phone":31,"phoneExt":31,"email":31},"PRINCIPAL_INVESTIGATOR",{"type":61,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[63],{"name":64,"class":65},"National Institute for Health Research, United Kingdom","OTHER_GOV","100564110","early-phase-1-losartan-and-social-processing-100564110",false,"NCT06624904","Losartan and Social Processing","The Effects of Single-dose Losartan on Social Processing in Healthy Adults: a Randomized Controlled Study","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Aged 18-50 years\n* Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires\n* Non- or light-smoker (5 cigarettes a day, if vaping: less than 50 puffs)\n* BMI between 18 - 30\n\nExclusion Criteria:\n\n* Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder\n* First-degree family member with severe psychiatric illness (including psychosis, bipolar disorder, unipolar psychotic depression).\n* CNS-medication last 6 weeks (including as part of another study)\n* Current blood pressure or other heart medication, including aliskiren and beta blockers)\n* Diagnosis of intravascular fluid depletion or dehydration\n* History of angioedema\n* Impaired kidney function (based on self-report)\n* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F50 mmHg (in accordance with established standard definitions)\n* Lifetime history of epilepsy or other neurological disorder, as established by a professional diagnosis (e.g. autism, ADHD)\n* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study\n* Significant loss of hearing that is not corrected with a hearing device\n* Women: pregnancy (as determined by a urine test, if the participant's pregnancy status is unknown during the in-person visit), breast-feeding",true,"ALL","18 Years","50 Years",{"count":78,"type":79},68,"ESTIMATED","INTERVENTIONAL",[82],"EARLY_PHASE1","This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.",[85],"Social Cognition",[87,9,88],"Social Processing","Renin Angiotensin System","2025-07-23",{"date":91,"type":92},"2025-07-28","ACTUAL",{"date":94,"type":92},"2024-08-19",{"date":96,"type":79},"2025-10-01",{"name":5,"class":6},1]